michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, good question, Mark. Thanks. We're really focused on efficiency and I think our expenses are likely at a good run rate, where we sit now. So, that impact, as we go through the year, is really more of the second part of your premise, which is the seasonally high collections in the first quarter here. And that's really going to be what will drive that over the course of the year.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
No. What was great this quarter was when you look at the makeup of backlog in terms of how we add to backlog year-over-year, it came from all key buckets: cross-sell, renewals and new. We saw a really good growth in net new bookings year-over-year, which Matt mentioned, all three quarters this year. We've seen really good year-over-year growth in cross-sell. And then, we had the best quarter of renewals this quarter that we've seen in a while back. The quarter for Q3 in terms of renewals that add to backlog was greater than the first half in its entirety. So it was a great mix for us to see all three of those areas the business deliver. And we certainly see Q4 historically has been a really strong renewal quarter. We see that opportunity again this Q4. And if we pull some of those renewals in from Q1, it could put some pressure on Q1 backlog, but we feel really good about how we're [Indecipherable] Q4.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
It's a good question, it's hard to say, I mean, and it's anecdotal. I'd say you go down the list of Top 20 pharma and deeper and each each entity has a differing fervor of adoption and a different means of adoption, meaning, we're trying to change the development cycle in total or are we implementing a modeling and simulation approach in the therapeutic area or in a particular segment of their effort and the industry is across the map in terms of those approaches. I do believe -- and from our perspective the market is not a one-platform market.
There is no one solution that becomes the basis for your modeling and simulation, your model-based drug development program. There are a number of techniques and platforms that come into play here and that is behind in part our expansion GastroPlus, ADMET Predictor, our acquisition of Monolix last year is to be in a position to provide our clients all of the technical platforms that can contribute to a model-based drug development program and provide it to them efficiently in terms of a vendor partner that can supply their needs as well as technically under the covers platforms that are -- have an ability to talk to each other and can be integrated, if not immediately over time, to make that process most most efficient.
So, I'd say that you got to take a look at the market and there are some leaders, there are some laggards and the vast majority are somewhere in the middle there and in terms of partially and with different strategies implementing. All I would say of all those characterizations types of clients, if you compare them today versus a year ago versus five years ago, today their devotion to model-based drug development is greater than it was in those time references.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Significant incentivizing up in Boston. Very little activity at all in California, which is snapping back beautifully and the same here at Pike & Rose. In fact, the leader, by the way, among those three in terms of rent growth and -- or lack of rent ammunition is Pike & Roses.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
We're very active there, Ryan. I think it's just opportunistic. We've built RPS over the last 20-plus years in large part with acquisitions. And we've done some nice acquisitions over the last 12 months in RPS. One of the areas we've built out, of course, we're the country's largest MGA. We also have a program business that's really strong. But open market brokerage, we've built the typical Gallagher way. We recruited our own and built our own young people out of our internship, and we've done some very nice acquisitions there. So no, there's no hold back there. And actually, there's no real shortage of opportunities, a lot of competition, one of which had a very successful IPO this month.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I think over the next 12 months, certainly, we have plenty of room to grow the balance sheet without adding additional capital. I mean, we've said before, we're sitting at $3.3 billion. We certainly have room to go to $4 billion pretty easily from a capital standpoint. We've had tremendous asset purchase success this year.
We've just seen a huge amount of prepayments coming from a lot of the asset classes. That's -- and so it's been difficult growing that portfolio. We are working on some transactions, hopefully, that we can talk about in our fourth quarter call that should accelerate some of the pipeline opportunities. Jason, go ahead, too.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
In line, we explained during the merge operation.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I wouldn't have integrated it during a global pandemic, but we did. We migrated the systems very successfully. People didn't think we could do that. We did that very successfully to the teeth of a pandemic. We're now benefiting from that single SAP instance. I think we integrated that business pretty well given the conditions that we were in. And certainly, we see that deal now really paying off. It's really -- as we hit our operational stride, we really see the benefits of that deal paying off.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good afternoon. Thanks for taking my question. I appreciate all the detailed guidance. I guess, overall, if I have all the numbers down correctly, I think the guide implies EBIT margins down about 250 basis points this year versus 2019. Could you characterize, I mean, how much of the step-down is related to the COVID costs, which are hopefully temporary versus some of the more pressures on freight and wages that could persist moving forward? Just trying to think about how that EBIT margin might progress as we move beyond this year. Thank you.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. The only thing I would add to that, Jackie, would be the continued paydown via the refinances that we're having in the residential real estate and recognizing that those continue to flow over into especially the small balanced real estate loans, and lot of the consumer small balance loans often are secured by home equity as well when they are underwritten. So you'll continue to see some of that roll off with the strong mortgage market, refinance market.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. We're expecting to see a very good back-to-school season to be comparable, if not better than 2019, and we're prepared for that. So -- and then as it relates to the channel tax credit, we did see sales pick up mid-July relative to our plan. I would say it was a relatively short-lived and it was obviously a smaller benefit than stimulus check that was received earlier this year. But we saw business pick up, and it picked up for a week or so and then settled back down closer to our plan. So the nice thing about the enhanced child tax credit. Those are six monthly payments in the balance of this year. And then the second half of the annual benefit we paid early part of next year. So we'll continue to see whether or not that continues to benefit us in each of the months in the balance of the year. But it's a meaningful benefit for families with young children. For children under the age of six, I think the payment -- the tax credit improved by some portion from about 80% to about $3,600 a year for children under the age of six. So it should be good for families with young children and might be a potentially good benefit for us.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Great. Hi, Andre, Simon and Carrie. Thank you very much for taking the questions. I just had one on UCART22. Could you clarify what you mean by the correlated analysis of cell expansion and persistence? Do you mean correlation of cell expansion and persistence with response? And will this analysis determine whether you need to adjust the lymphodepletion regimen?
And then a separate financial question. You just -- could you just comment where you stand with respect to your stake in Calyxt? Is that something you would consider selling to further finance the Company? Thank you.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, thanks for taking my question. Commendable job specifically on the operating margin side guys. Looking here, I did want to ask some of the questions I had have already been addressed. But looking at how strong the Opto division has been, we've been hearing a lot of things about shortages and high demand out of that area. Is there any elaboration you could provide about specific areas of strength, whether it's like specific products and demand and where is that feeding into from like a geographic region?

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. No, I think -- I think 516 -- I think 500 and 516 in the solid tumor setting at some basic level, proof of concepts, understanding sort of translational learnings and incorporating those into certainly, 538, and then even more complex engineered cell therapies that have direct targeting like the three products I alluded to, FT536, FT573 and the first Janssen product candidate. So I think the true test in solid tumors at the end of the day, while I think we can absolutely gain learnings from 500 and 516. I think the true test and to maximize patient benefit is certainly with a multiplexed engineered cell therapy in solid tumors.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you, Shar.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Phil, that's a very important question, and that's -- you know, thanks for asking. Because wind and wind hybrid, currently, what is happening is a bit odd. It's still stand-alones, very small storage standards, which are more exploratory in nature than commercial in nature. So we have looked at some of them.
We have not yet taken part in any of those auctions because they're very small and exploratory like I said. However, as wind and solar-wind hybrid projects are concerned, they are very established. Wind has been around in India for more than 25 years. So, therefore, it's a well-established market.
And Murali and I have the experience of building more than one gigawatt of wind in our previous life. So, therefore, you know, we are very, very comfortable with wind options, and wind projects, and wind construction, and wind operation. So we have taken part in an auction for wind and an option for solar-wind hybrid in the last six months. And there are a couple of auctions coming up over the next -- we understand, in the next four to six weeks.
So we will take part in those auctions. And if -- again, if we find that the right tariffs, we will certainly, you know, like to win one of those auctions and win both those auctions, and build out, you know, the first wind or wind/solar hybrid projects for Azure.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
No. We are actively talking with customers. And as we close the quarter, there are provisions for what we believe those concessions to be as we stand here today.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So true.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Well, we think about an investment like that, you know, a number of ways. But if we look at trend pricing and we think about the synergies with the pulp mill that's the better than three year payback on that capital, potentially. And in peak pricing, it'll be better. And then trough pricing it'll be worse obviously, but there's a tremendous synergy there. You can imagine every log sitting in front of the pulp mill that's going to be going through a scanner and it's going to say, hey that's not really a pulp log, that's a saw log, that's called -- this one is a saw logs. So we're going to be harvesting saw logs out of a pulp log. While a wood if you like and there is just a really strong maturing timber supply in and around the central region. So it will be the main sawmill in the region enjoying that and basically what you're doing is, you're providing the lowest cost shift to the pulp mill displacing its highest cost fibre, the stuff that you would have been bringing in from the Baltics or places like that. So there's, it's a bit like free shell in that way. It's in relation to the EBITDA from the sawmill, there's a there's a real benefit to the pulp mill.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, no happy to Greg. Appreciate you joining today love the question. So first is we are accelerating as we've been talking about the last several quarters. Our overall sales performance, our sales pipeline is as large and has as many large late stage deals in that pipeline. And our closure rate continues to be quite strong, and we love what we're seeing in the market. So one is just the underlying performance of our sales teams.
Secondly, when you look at the renewals, and you see what's going on in the North American broadband industry with the number of subscribers that our customers are adding, it's fantastic to see their success and their growth. And CSG is a main partner and platform provider, we're benefiting from the overall rising water level of the industry.
And then third, we continue to expand the offerings in the business that we win with our existing and our new customers. And so with the charter announcements, what's also factored in, along with the any discount we gave him was the fact that we're gaining significant number of subscribers. And we'll be migrating those onto our platforms like we've done in 2021, but in an accelerated fashion over the next 12, 18 months. So it's really all of those things are going into the growth in the guidance that we gave preliminarily for 2022 for both top line, adjusted revenue and the operating margin as well staying consistent with that 16.5% to 17% range.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. Thank you.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, as I said before, we are very committed to the industry and to support the growth of the industry independently on where these demand will take place. So, of course, we are considering and preparing ourselves for scenarios in which you will have more demand of lithium either in Europe or in North America. So, yeah, there is no -- we do not see a big -- a big challenge. Actually, due to the business in nitrate that we have today, we have already established in Europe a very strong network of warehousing same as in the U.S. Remember that we sell more than 900,000 tons of nitrate. So, we are prepared to handle big volumes in different markets. So, I'm not particularly concerned about building up supply chain to Europe or the U.S.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I cannot exclude it, but this is not a driving thing I believe. I don't -- sorry, it can happen of course. And these times speak -- it can happen especially in such times, but I don't see a momentum here no.

    Prediction (one of UP, DOWN, SAME): SAME